Search
ZALTRAP 25 MG / ML, Solution à diluer pour perfusion
Details
| --- | Description |
|---|---|
| Pack | Boite d'un flacon de 4 ML de solution |
| Strength (Dosage) | 25 MG / ML |
| Laboratory | SANOFI AVENTIS MAROC |
| Ingredients | Aflibercept |
| Therapeutic class | Antinéoplasique, protéine de fusion (anti-VEGF) |
| ATC code | L01XX44 |
| PPH | $373.10 |
| PPV | $402.40 |
| Refundable | Yes |
| Refund base | $402.40 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | ZALTRAP en association avec la chimiothérapie irinotécan/5-fluorouracile/acide folinique(FOLFIRI) est indiqué chez les adultes atteints d’un cancer colorectal métastatique (CCRM) résistant ou ayant progressé après un traitement à base d’oxaliplatine. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem